Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
The price of Sangamo Therapeutics Inc (NASDAQ: SGMO) closed at $0.74 in the last session, down -5.93% from day before closing price of $0.79. In other words, the price has decreased by $-5.93 from its previous closing price. On the day, 3.86 million shares were traded. SGMO stock price reached its highest trading level at $0.7979 during the session, while it also had its lowest trading level at $0.7223.
Ratios:
We take a closer look at SGMO’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 1.13 and its Current Ratio is at 1.13. In the meantime, Its Debt-to-Equity ratio is 1.34 whereas as Long-Term Debt/Eq ratio is at 1.15.
On December 10, 2024, H.C. Wainwright reiterated its Buy ratingand also kept the price unchanged to $10.
RBC Capital Mkts Downgraded its Outperform to Sector Perform on November 03, 2023, whereas the target price for the stock was revised from $6 to $2.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SGMO now has a Market Capitalization of 172250048 and an Enterprise Value of 155000832. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.88 while its Price-to-Book (P/B) ratio in mrq is 6.92. Its current Enterprise Value per Revenue stands at 2.682 whereas that against EBITDA is -1.662.
Stock Price History:
The Beta on a monthly basis for SGMO is 1.44, which has changed by 0.45098042 over the last 52 weeks, in comparison to a change of 0.097913146 over the same period for the S&P500. Over the past 52 weeks, SGMO has reached a high of $3.18, while it has fallen to a 52-week low of $0.30. The 50-Day Moving Average of the stock is -13.68%, while the 200-Day Moving Average is calculated to be -37.92%.
Shares Statistics:
According to the various share statistics, SGMO traded on average about 6.64M shares per day over the past 3-months and 4768020 shares per day over the past 10 days. A total of 224.71M shares are outstanding, with a floating share count of 214.84M. Insiders hold about 4.50% of the company’s shares, while institutions hold 27.72% stake in the company. Shares short for SGMO as of 1744675200 were 29709429 with a Short Ratio of 4.47, compared to 1741910400 on 28913359. Therefore, it implies a Short% of Shares Outstanding of 29709429 and a Short% of Float of 13.29.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
A detailed examination of Sangamo Therapeutics Inc (SGMO) is currently in progress, with 1.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is $-0.14, with high estimates of $-0.14 and low estimates of $-0.14.
Analysts are recommending an EPS of between $-0.34 and $-0.34 for the fiscal current year, implying an average EPS of $-0.34. EPS for the following year is $-0.35, with 1.0 analysts recommending between $-0.35 and $-0.35.
Revenue Estimates
For the next quarter, 6 analysts are estimating revenue of $43.73M. There is a high estimate of $200M for the next quarter, whereas the lowest estimate is $400k.
A total of 7 analysts have provided revenue estimates for SGMO’s current fiscal year. The highest revenue estimate was $200M, while the lowest revenue estimate was $14.9M, resulting in an average revenue estimate of $62.23M. In the same quarter a year ago, actual revenue was $57.8MBased on 7 analysts’ estimates, the company’s revenue will be $49.99M in the next fiscal year. The high estimate is $114.2M and the low estimate is $9.9M.
